PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

PeproMene Bio, Inc. announced a patient in their Phase 1 trial for PMB-CT01 (BAFFR-CAR T Cells) achieved complete remission post-treatment for relapsed/refractory B-cell acute lymphoblastic leukemia. The trial, conducted at City of Hope, showed minimal toxicity and durable remissions, highlighting PMB-CT01's potential in treating B-cell malignancies.